TB-500
TB-500 appears in 1,172 indexed publications going back to 1982, including 31 in the past twelve months. 15 registered trials appear on ClinicalTrials.gov.
On This Figure
Most of this literature studies thymosin beta 4, the endogenous protein TB-500 is derived from, rather than the TB-500 fragment itself.
Publication history
How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.
Publications per year. The final bar is the current year, still in progress.
| 2015 | 45 |
|---|---|
| 2016 | 36 |
| 2017 | 38 |
| 2018 | 43 |
| 2019 | 27 |
| 2020 | 22 |
| 2021 | 42 |
| 2022 | 24 |
| 2023 | 34 |
| 2024 | 13 |
| 2025 | 26 |
| 2026 | 22 |
Who is looking it up
Monthly readers of the TB-500 article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.
The registered pipeline
Phase distribution across the most recently updated registered trials.
- Not yet recruiting·Phase 2
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
Beijing Northland Biotech. Co., Ltd. · estimated completion 2027-08-17
- Recruiting·Phase 1
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Hudson Biotech · estimated completion 2027-02-14
- Recruiting·Phase 3
ReGenTree, LLC · completed 2026-04-30
- Terminated·Phase 3
ReGenTree, LLC · completed 2019-11-20
- Completed·Phase 3
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLC · completed 2020-11-08
- Completed·Phase 3
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
ReGenTree, LLC · completed 2017-09
Most recent work
The newest indexed records mentioning TB-500, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.
- 2026-08-01·Clinical science (London, England : 1979)
Thymosin β4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway
Ouyang X, Long Z, Xu X et al.
- 2026-07-01·Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Li YX, Chen CL, Zheng SD et al.
- 2026-07-10·Experimental eye research
Banga L, Shawky M, Ebrahim F et al.
- 2026-03-31·Bioengineering & translational medicine
PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
Peng H, Chai Y, Gong C et al.
- 2026-07-01·Current sports medicine reports
Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review
Nguyen C, Allen MR, Hornburg K et al.
- 2026-06-01·Investigative ophthalmology & visual science
Ebrahim AS, Liu L, Carion TW et al.
- 2026-05-22·Biomolecules
Ye Y, Yang X, Liu Y et al.
- 2026-04-01·Integrative medicine (Encinitas, Calif.)
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation
Mazza AD. et al.
Sources
Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.